(Total Views: 528)
Posted On: 08/15/2022 10:26:41 PM
Post# of 145254
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
also in the news today gsk will not take their option with ideaya ide397 re tumors.
"The resulting MAT2A inhibitor is called IDE397. But in a second-quarter earnings this morning, Ideaya revealed that GSK has waived its rights to exercise an option for the exclusive license to IDE39 or any other MAT2A-targeting compounds Ideaya will work on."
'
"The resulting MAT2A inhibitor is called IDE397. But in a second-quarter earnings this morning, Ideaya revealed that GSK has waived its rights to exercise an option for the exclusive license to IDE39 or any other MAT2A-targeting compounds Ideaya will work on."
'
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)